DYNDyne Therapeutics Inc
Mkt Cap
$2.33BVolume
1.76M52W High
$35.6852W Low
$6.36PE Ratio
-4.23DYN Fundamentals
Price
$16.35Prev Close
$16.75Open
$16.7550D MA
$13.60Beta
1.61Avg. Volume
2.45MEPS (Annual)
-$3.37P/B
3.27Rev/Employee
$0.00Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·3mo ago
Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises
Investing.com -- U.S. stock futures slipped lower Tuesday, dropping back from record levels as investors digested the latest news on trade deals, the Trump administration’s tax bill as well as upcoming key economic data.
investing.com·4mo ago
Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance
investing.com·4mo ago
Raymond James bullish on biotech firms on favorable valuation
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”
investing.com·4mo ago
Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
investing.com·6mo ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1y ago